Slide 1. Slide 2. Slide 3. Objectives. Why should we care about the elderly? Antiseizure Drugs in Elderly Patients

Size: px
Start display at page:

Download "Slide 1. Slide 2. Slide 3. Objectives. Why should we care about the elderly? Antiseizure Drugs in Elderly Patients"

Transcription

1 Slide 1 Antiseizure Drugs in Elderly Patients Angela Birnbaum, Ph.D. Professor Epilepsy Research and Education Program Center for Clinical and Cognitive Neuropharmacology College of Pharmacy University of Minnesota Slide 2 Objectives 1) Discuss epilepsy in elderly patients 2) Discuss how pharmacokinetics change in the elderly 3) Learn about antiseizure drugs 4) Medication management Slide 3 Why should we care about the elderly?

2 Incidence per 100, Percentage Slide 4 Growth of the Elderly in the U.S. population % % Year From: Taeuber, Bureau of the Census Slide 5 Age-Specific Incidence of Epilepsy by Gender in Rochester, Minnesota Males Females Total Annegers JF, et al. Epilepsia. 1995;36: Hauser WA, et al. Epilepsia. 1993;34: Age (years) [5] Slide 6 Etiology of Epilepsy, Age % 5% 2% 2% 51% Cryptogenic 51% Stroke 38% Degenerative 12% Tumor 5% 38% Trauma 2% Infection 2% Hauser WA, et al. Epilepsia. 1993;34:

3 Health Status Slide 7 Incidence of Epilepsy/Seizure Cases in US Nursing Homes For incidence in US nursing homes - All residents of any US Medicare/Medicaid certified NH - From Excluded those with epilepsy on admission - Excluded those with less than 3 years of MDS Among 3,613,926 residents followed forward - 1,640 new-onset epi/sz cases/100,000 patient-years - 12 times higher than in the community dwelling elderly - Approximately 20 times the rate in young adults Leppik, Eberly, Harms, Birnbaum, Journal of the American Medical Directors Association, vol 12(3), 2011 Slide 8 Health Status of Elderly Patients Not all elderly patients are alike Age Young healthy Young Medical problems Young frail Middle healthy Middle Medical Problems Middle frail Old healthy Old Medical problems Old frail Slide 9 Characteristics of Elderly Groups Elderly not homogenous Community dwelling elderly similar to young Frail population Nursing home High number of co-medications High number of ASD (~10%) High number of co-morbidities Very limited drug concentration data available

4 Slide 10 Considerations in Geriatric Epilepsy Management Aging Process Underlying Pathology Management Seizure Frequency Comorbidities Medication Side Effects Pharmacokinetics Slide 11 Pharmacotherapy in the Elderly Slide 12 Goals of Epilepsy Care Eliminate seizures with no side effects; alternatively Reduce the number Decrease the severity Minimize side effects Optimize quality of life Excitation Glutamate Aspartate Normal CNS Function Inhibition GABA

5 Slide 13 Chronology of ASD Development 1st generation ASDs 2 nd generation ASDs Year Drug Year Drug 1912 Phenobarbital 1993 Felbamate 1938 Phenytoin 1994 Gabapentin 1947 Mephenytoin (no longer available) 1994 Lamotrigine 1954 Primidone 1996 Topiramate 1960 Ethosuximide 1997 Tiagabine 1968 Diazepam 1999 Oxcarbazepine 1974 Carbamazepine 1999 Levetiracetam 1975 Clonazepam 2000 Zonisamide 2005 Pregabalin 1978 Valproate 2009 Rufinamide 2009 Vigabatrin 2011 Clobazam 3 rd generation ASDs Year Drug 2009 Lacosamide 2011 Ezogabine 2012 Perampanel 2013 Eslicarbazepine Slide 14 Indications for ASDs Epilepsy Headache Psychiatric disorders Neuropathic pain Behavior Weight loss Movement disorders Spasticity Slide 15 Medication Selection Seizure type Co-medications Medical conditions Age of the patient Insurance coverage Allergies Adherence challenges

6 Slide 16 New onset seizures Seizure Type Partial Onset Generalized Absence First Line Therapy Carbamazepine Gabapentin Lamotrigine Oxcarbazepine Phenobarbital Phenytoin Topiramate Valproic Acid Lamotrigine Topiramate Valproic Acid Lamotrigine Ethosuximide Valproic Acid Slide 17 What is an Adverse Drug Reaction? Definition: An unexpected or dangerous reaction to a drug or an unwanted effect caused by the administration of a drug Adverse Event and Side Effect You may not experience an adverse event Usually happens within the first month No absolutely safe drug exists Most are minor - diarrhea, headache, etc. Some are serious Slide 18 What is a Medication Interaction? Definition: A measurable modification of the action of one drug by another substance (medication, herbal product, dietary supplement, etc) May cause adverse drug reactions Minor (temporary symptoms) or Serious (life threatening reactions) May occur when starting or stopping a medication Preventable Adverse Drug Reactions: A focus on drug interactions.

7 Slide 19 Herbs: Natural Safe Herbal products are not well regulated Lack of data that they work for what is claimed Lack of data about safety Other active ingredients not identified Amount of active ingredients in each bottle not guaranteed May interact with prescription medications Just because it s natural doesn t mean it s safe - warfarin and St. John s wort Slide 20 Types of Drug Interactions Drug-drug: Valproic acid and lamotrigine Drug-food: Carbamazepine and grapefruit juice Drug-dietary supplement: Calcium and phenytoin Drug-herbal: warfarin and St. John s Wort Drug-disease: medications that lower the seizure threshold and epilepsy Slide 21 Pharmacokinetics in the Elderly

8 Slide 22 bsorption istribution etabolism limination Absorption Body Metabolism Enzymes Elimination Distribution Tissue Distribution Plasma Protein Binding Slide 23 As we age. Absorption Blood flow to stomach and intestines Acidity Stomach emptying Intestinal motility Distribution Muscle Fat Metabolism Blood flow to liver Size of liver/# hepatocytes Excretion Blood flow to kidneys Size of kidneys Ability to filter As a result drug interactions can change over time There are few studies characterizing ASD pharmacokinetics in the elderly Slide 24 Pharmacokinetic Characteristics Desired PK Antiseisure Characteristics Drugs Multiple formulations Yes Yes & No Birnbaum 2012 Protein binding (>85%) Low Low & High Metabolized by liver No Yes & No Induces/inhibits liver metabolism No Yes & No Renally cleared Yes Yes & No Type of Pharmacokinetics Linear Linear & Nonlinear

9 Slide 25 Pharmacokinetics: Does it matter? 76 year old woman Referred in new onset Seizures Dementia Cerebellar degeneration Arrived in wheelchair Scheduled for nursing home placement Total drug concentration measurements phenytoin total - 19 mg/l (normal mg/l) valproate total - 86 mg/l (normal mg/l) Slide 26 Pharmacokinetics: Does it matter? Stopped drug Unbound concentrations phenytoin - >2 mg/l (normal 1-2 mg/l) valproate - 22 mg/l (normal 6-15 mg/l) Left hospital walking on own Loved to dance with husband What happened pharmacokinetically? Protein binding - >80% Inhibition of metabolism Slide 27 Co-Medication Use in Elderly Nursing Home Residents on ASDs Drug Category Antidepressants Antipsychotics 19% 12.7% Benzodiazepines 22% Thyroid Supplements Antacids Antiseizure Drugs 14% 8% 12% Maintenance Medication Use by Elderly Nursing Home Residents Calcium Channel Blockers Warfarin Cimetidine 7% 5.9% 2.5% + ASD ASD 6 meds 5 meds % of Antiseizure Drug Recipients 30 Lackner, Cloyd, Thomas, Leppik, Epilepsia 39: , 1998

10 Slide 28 Epilepsy and stroke Number one cause of epilepsy in people older than 50 Side effects of medicine can make the effects of the stroke a little worse Make sure you know about any other medications and if it is safe to mix with any epilepsy medications efmn.org Slide 29 How to Optimize ASD Therapy Titrate dose or serum concentration to response Increase dose until seizure control is attained; or until unacceptable side effects occur Consider adding 2nd ASD if first is not effective Individual ranges May be different than suggested therapeutic range Slide 30 Only the right dose differentiates between a poison and a remedy Paracelsus,

11 Percent of Residents Slide 31 Antiseizure drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies When therapeutic response is reached When steady state dosing is reached 5 half lives When new drug added or other drug removed if there is potential for drug interaction Hepatic Absorption Renal elimination Toxicity Therapeutic Drug Monitoring Breakthrough seizure Slide 32 Interpreting ASD concentrations Suggested therapeutic ranges based on younger adults Concentrations will fluctuate due to: - absorption, elimination, time, and laboratory assays For younger adults - older ASDs (PHT, CBZ, VPA) CV 20-25% Elderly - <30%? - nursing home elderly may be more variable Slide 33 Total PHT Concentrations in Nursing Home Residents Beverly Enterprises Nursing Homes - First Collected Blood Draw % 46% 9% N = 387, 65 years Women = 67% Mean Cp = 11.7 ± 6.4 ug/ml Mean dose = 4.9 ± 1.8 mg/kg <5 5-<10 10-<15 15-<20 20-<25 25-< Total PHT Concentration (ug/ml) Birnbaum, Hardie, Conway, Bowers, Lackner, Graves, Leppik, AJGP vol 1(2): 90-95, (Dec 2003)

12 Total PHT Concentrations (ug/ml) Percent of Residents Slide 34 Valproic Acid Dose in Nursing Home Residents Beverly Enterprises Nursing Homes - First Collected Blood Draw Psychiatric Seizure < >100 Total VPA Concentration (ug/ml) N = 146 Women = 64% Dose (mg/kg) = 19.4 ± = 16.3 ± = 11.3 ± 7.6 p =0.003 Cp (ug/ml) = 56.4 ± = 47.7 ± = 38.7 ± 23.1 p = Birnbaum, Hardie, Conway, Bowers, Lackner, Graves, Leppik, Epilepsy Research 62(2-3); ; 2004 Slide 35 Expected Concentration Pattern with Chronic Dosing Too high: Side effects! Too low: Seizures! Time of Dose Time of Dose Time of Dose Slide 36 Individual Total Phenytoin Serum Concentrations in Elderly Nursing Home Residents 35 Aged Aged Aged (n=18) (n=21) (n=17) Individual Elderly Residents Categorized by Age Group at Enrollment Birnbaum, Hardie, Leppik, Conway, Bowers, Lackner, Graves, Neurology, 60: (2003)

13 Slide 37 Interpreting Drug Concentrations Variability in total ASD concentrations in some Why? Absorption? Metabolism? Protein binding? Kidney? Do NOT change ASD doses based on ONE level No need to measure total ASD levels? Editorial: Lesser, Neurology 60: ; Journal Watch: vol23(7):56 Assess pharmacokinetic possibilities May need to measure unbound ASDs? May need to record adverse events when drawing blood samples? Are there possibly interacting medications? Is a medication being added or removed? Slide 38 Organizing Medications to Minimize Issues Slide 39 Systems for Increasing Medication Adherence Pill boxes Decrease forgotten doses Helps prevent taking extra doses Calendar or check list Timers Medication placement By the kitchen sink By the night stand Pre-packaged by the pharmacy Involving household members

14 Slide 40 Is it safe to take with other medicine including over-the-counter medicine, vitamins, or herbals? Many medications are involved in a lot of drug interactions If you use the same pharmacy (or chain pharmacy) this can be checked quickly Drug interaction software Does not always include herbal products May take the pharmacist some time to research Slide 41 Avoiding Interactions - Prevention Maintain a list of ALL the drugs and supplements My medicine list Keep it updated Keep lists in wallet or purse Share lists with physicians and pharmacists Include all medications: prescription and over the counter Supplements Herbal supplements See if there are questions before beginning a new product Most drug interactions can either be prevented or managed Slide 42

15 Slide 43 Overall Pharmacy Tips Use the same pharmacy Drug history in one place Check for drug interactions Get to know the staff Better customer service A few to get by Help with vacation supplies Pharmacists are available when other healthcare providers are not (evenings, weekends) Recommend less expensive alternatives Slide 44 Where to find drug information Your Pharmacist Web sites Product sites Slide 45 Want more assistance? Medication Therapy Management (MTM) Pharmacist reviews medications Makes recommendations Works with your providers Medicare part D benefit Contact your insurance to see if you have the benefit and to find a pharmacist providing services

16 Slide 46 Conclusions The incidence of epilepsy in the elderly is high Pharmacokinetic issues are probable in the elderly - Physiological changes as we age - Presence of high number of co-medications - Presence of co-morbidities Populations of elderly may have different PK issues - concentrations variable in some nursing home elderly - elderly may be more sensitive to drug = lower doses Optimize dosing administration Identify possible drug issues - interactions

Disclosure. Learning Objectives

Disclosure. Learning Objectives Linda D. Leary, M.D. Associate Clinical Professor of Pediatrics & Neurology South Texas Comprehensive Epilepsy Center UT Health Science Center San Antonio Disclosure Linda D. Leary, M.D. discloses the

More information

Epilepsy 101. Overview of Treatment Kathryn A. O Hara RN. American Epilepsy Society

Epilepsy 101. Overview of Treatment Kathryn A. O Hara RN. American Epilepsy Society Epilepsy 101 Overview of Treatment Kathryn A. O Hara RN American Epilepsy Society Objectives Describe the main treatment options for epilepsy Identify factors essential in the selection of appropriate

More information

Epilepsy is a very individualized

Epilepsy is a very individualized ... PRESENTATION... Treatment of Epilepsy in 3 Specialized Populations Based on a presentation by Ilo E. Leppik, MD Presentation Summary When discussing the treatment of epilepsy, targeted populations

More information

Ernie Somerville Prince of Wales Hospital EPILEPSY

Ernie Somerville Prince of Wales Hospital EPILEPSY Ernie Somerville Prince of Wales Hospital EPILEPSY Overview Classification New and old anti-epileptic drugs (AEDs) Neuropsychiatric side-effects Limbic encephalitis Non-drug therapies Therapeutic wishlist

More information

The Epilepsy Prescriber s Guide to Antiepileptic Drugs

The Epilepsy Prescriber s Guide to Antiepileptic Drugs The Epilepsy Prescriber s Guide to Antiepileptic Drugs The Epilepsy Prescriber s Guide to Antiepileptic Drugs Philip N. Patsalos FRCPath, PhD Professor of Clinical Pharmacology and Consultant Clinical

More information

New Onset of Epilepsy in the Elderly Dec 6, 2013

New Onset of Epilepsy in the Elderly Dec 6, 2013 New Onset of Epilepsy in the Elderly Dec 6, 2013 Ilo E. Leppik, MD Professor of Neurology and Pharmacy University of Minnesota American Epilepsy Society Annual Meeting Disclosure During my almost 40 years

More information

2018 American Academy of Neurology

2018 American Academy of Neurology Practice Guideline Update Efficacy and Tolerability of the New Antiepileptic Drugs I: Treatment of New-Onset Epilepsy Report by: Guideline Development, Dissemination, and Implementation Subcommittee of

More information

AED Treatment Approaches. David Spencer, MD Director, OHSU Epilepsy Center Professor, Department of Neurology

AED Treatment Approaches. David Spencer, MD Director, OHSU Epilepsy Center Professor, Department of Neurology AED Treatment Approaches David Spencer, MD Director, OHSU Epilepsy Center Professor, Department of Neurology Audience Response Keypads Please utilize the keypad at your table to answer questions throughout

More information

Epilepsy and EEG in Clinical Practice

Epilepsy and EEG in Clinical Practice Mayo School of Professional Development Epilepsy and EEG in Clinical Practice November 10-12, 2016 Hard Rock Hotel at Universal Orlando Orlando, FL Course Directors Jeffrey Britton, MD and William Tatum,

More information

Prescribing and Monitoring Anti-Epileptic Drugs

Prescribing and Monitoring Anti-Epileptic Drugs Prescribing and Monitoring Anti-Epileptic Drugs Mark Granner, MD Clinical Professor and Vice Chair for Clinical Programs Director, Iowa Comprehensive Epilepsy Program Department of Neurology University

More information

Pharmacological Treatment of Non-Lesional Epilepsy December 8, 2013

Pharmacological Treatment of Non-Lesional Epilepsy December 8, 2013 Pharmacological Treatment of Non-Lesional Epilepsy December 8, 2013 Michael Privitera, MD Professor of Neurology University of Cincinnati, Neuroscience Institute American Epilepsy Society Annual Meeting

More information

Disease-Modifying, Anti-Epileptogenic, and Neuroprotective Effects of the Ketogenic Diet: Clinical Implications

Disease-Modifying, Anti-Epileptogenic, and Neuroprotective Effects of the Ketogenic Diet: Clinical Implications Disease-Modifying, Anti-Epileptogenic, and Neuroprotective Effects of the Ketogenic Diet: Clinical Implications Special Lecture 6 th Global Symposium on Ketogenic Therapies for Neurological Disorders Jeju,

More information

Updated advice for nurses who care for patients with epilepsy

Updated advice for nurses who care for patients with epilepsy NICE BULLETIN Updated advice for nurses who care for patients with epilepsy NICE provided the content for this booklet which is independent of any company or product advertised NICE BULLETIN Updated advice

More information

Management of Epilepsy in Primary Care and the Community. Carrie Burke, Epilepsy Specialist Nurse

Management of Epilepsy in Primary Care and the Community. Carrie Burke, Epilepsy Specialist Nurse Management of Epilepsy in Primary Care and the Community Carrie Burke, Epilepsy Specialist Nurse Epilepsy & Seizures Epilepsy is a common neurological disorder characterised by recurring seizures (NICE,

More information

Seizure medications An overview

Seizure medications An overview Seizure medications An overview Andrew Zillgitt, DO Staff Neurologist Comprehensive Epilepsy Center Department of Neurology Henry Ford Hospital None Disclosures Objectives A lot to review!!!!! Look at

More information

Anticonvulsants Antiseizure

Anticonvulsants Antiseizure Anticonvulsants Antiseizure Seizure disorders Head trauma Stroke Drugs (overdose, withdrawal) Brain tumor Encephalitis/ Meningitis High fever Hypoglycemia Hypocalcemia Hypoxia genetic factors Epileptic

More information

Epilepsy Society Therapeutic Drug Monitoring Unit (TDM Unit) Chalfont Centre for Epilepsy Chesham Lane Chalfont St Peter Buckinghamshire, SL9 ORJ

Epilepsy Society Therapeutic Drug Monitoring Unit (TDM Unit) Chalfont Centre for Epilepsy Chesham Lane Chalfont St Peter Buckinghamshire, SL9 ORJ Epilepsy Society Therapeutic Drug Monitoring Unit (TDM Unit) Chalfont Centre for Epilepsy Chesham Lane Chalfont St Peter Buckinghamshire, SL9 ORJ users guide to therapeutic drug monitoring of antiepileptic

More information

2018 American Academy of Neurology

2018 American Academy of Neurology Practice Guideline Update Efficacy and Tolerability of the New Antiepileptic Drugs II: Treatment-Resistant Epilepsy Report by: Guideline Development, Dissemination, and Implementation Subcommittee of the

More information

Appendix. TABLE E-1 Study Variables and Associated ICD-9-CM, HCPCS, and CPT Codes. Codes. (1) Fracture locations

Appendix. TABLE E-1 Study Variables and Associated ICD-9-CM, HCPCS, and CPT Codes. Codes. (1) Fracture locations Page 1 Appendix TABLE E-1 Study Variables and Associated ICD-9-CM, HCPCS, and CPT Codes (1) Fracture locations Vertebral fracture Codes ICD-9-CM Diagnosis codes: 733.13, 805.xx, 806.xx ICD-9-CM Procedure

More information

New antiepileptic drugs

New antiepileptic drugs Chapter 29 New antiepileptic drugs J.W. SANDER UCL Institute of Neurology, University College London, National Hospital for Neurology and Neurosurgery, Queen Square, London, and Epilepsy Society, Chalfont

More information

Disclosures. AED Options. Epilepsy Pharmacotherapy: Treatment Considerations with Older AEDs

Disclosures. AED Options. Epilepsy Pharmacotherapy: Treatment Considerations with Older AEDs Epilepsy Pharmacotherapy: Treatment Considerations with Older AEDs BARRY E. GIDAL, PHARMD PROFESSOR SCHOOL OF PHARMACY & DEPT. OF NEUROLOGY Disclosures Speaking honoraria: UCB, Eisai, Sunovion Consultant:

More information

Integrating Sentinel into Routine Regulatory Drug Review: A Snapshot of the First Year. Risk of seizures associated with Ranolazine (Ranexa)

Integrating Sentinel into Routine Regulatory Drug Review: A Snapshot of the First Year. Risk of seizures associated with Ranolazine (Ranexa) Integrating Sentinel into Routine Regulatory Drug Review: A Snapshot of the First Year Risk of seizures associated with Ranolazine (Ranexa) Efe Eworuke, PhD Division of Epidemiology Office of Pharmacovigilance

More information

Medications for Epilepsy What I Need to Know

Medications for Epilepsy What I Need to Know Medications for Epilepsy What I Need to Know Safiya Ladak, BSc.Phm. Toronto Western Hospital, UHN Clinical Pharmacist, Neurology and Neurosurgery June 4, 2016 Learning Objectives Treatment options for

More information

I. Introduction Epilepsy is the tendency to have recurrent seizures unprovoked by systemic or acute neurologic insults. Antiepileptic drugs (AEDs)

I. Introduction Epilepsy is the tendency to have recurrent seizures unprovoked by systemic or acute neurologic insults. Antiepileptic drugs (AEDs) 1 2 I. Introduction Epilepsy is the tendency to have recurrent seizures unprovoked by systemic or acute neurologic insults. Antiepileptic drugs (AEDs) are those which decrease the frequency and/or severity

More information

TOP APS DRUGS - DIVALPROEX SODIUM BRAND NAME: DEPAKOTE (ER)

TOP APS DRUGS - DIVALPROEX SODIUM BRAND NAME: DEPAKOTE (ER) divalproex sodium TOP APS DRUGS - DIVALPROEX SODIUM BRAND NAME: DEPAKOTE (ER) Pharmacodynamics study of what a drug does to the body Divalproex sodium is chemically compounded from sodium valproate and

More information

11/7/2018 EPILEPSY UPDATE. Dr.Ram Sankaraneni. Disclosures. Speaker bureau LivaNova

11/7/2018 EPILEPSY UPDATE. Dr.Ram Sankaraneni. Disclosures. Speaker bureau LivaNova EPILEPSY UPDATE Dr.Ram Sankaraneni Disclosures Speaker bureau LivaNova 1 Outline New onset Seizure Investigations in patients with epilepsy Medical management of epilepsy Non Pharmacological options in

More information

Epilepsy: pharmacological treatment by seizure type. Clinical audit tool. Implementing NICE guidance

Epilepsy: pharmacological treatment by seizure type. Clinical audit tool. Implementing NICE guidance Epilepsy: pharmacological treatment by seizure type Clinical audit tool Implementing NICE guidance 2012 NICE clinical guideline 137 Clinical audit tool: Epilepsy (2012) Page 1 of 25 This clinical audit

More information

When choosing an antiepileptic ... PRESENTATION... Pharmacokinetics of the New Antiepileptic Drugs. Based on a presentation by Barry E.

When choosing an antiepileptic ... PRESENTATION... Pharmacokinetics of the New Antiepileptic Drugs. Based on a presentation by Barry E. ... PRESENTATION... Pharmacokinetics of the New Antiepileptic Drugs Based on a presentation by Barry E. Gidal, PharmD Presentation Summary A physician s choice of an antiepileptic drug (AED) usually depends

More information

Pharmacology 101: Anti-Epileptic Drugs

Pharmacology 101: Anti-Epileptic Drugs Pharmacology 101: Anti-Epileptic Drugs DSF Biennial Family Conference July 21, 2018 Michelle Welborn, PharmD Objectives Receive Practical Advice Regarding Prescription Medications Understand the Absorption,

More information

Epilepsy Medications: The Basics

Epilepsy Medications: The Basics Epilepsy Medications: The Basics B R I A N A P P A V U, M D C L I N I C A L A S S I S T A N T P R O F E S S O R, D E P A R T M E N T O F C H I L D H E A L T H A N D N E U R O L O G Y, U N I V E R S I T

More information

improving the patient s quality of life.

improving the patient s quality of life. Epilepsy is the tendency to have recurrent seizures unprovoked by systemic or acute neurologic insults. Antiepileptic drugs (AEDs) are those which decrease the frequency and/or severity of seizures in

More information

ESETT OUTCOMES. Investigator Kick-off Meeting Robert Silbergleit, MD

ESETT OUTCOMES. Investigator Kick-off Meeting Robert Silbergleit, MD ESETT OUTCOMES Investigator Kick-off Meeting Robert Silbergleit, MD Primary objective The primary objective is to determine the most effective and/or the least effective treatment of benzodiazepinerefractory

More information

New AEDs in Uncontrolled seizures

New AEDs in Uncontrolled seizures New AEDs in Uncontrolled seizures Uncontrolled seizures/epilepsy Intractable epilepsy, Refractory epilepsy, Pharmacoresistant epilepsy Dr. Suthida Yenjun Traditionally, referred to therapeutic failure

More information

Valproate Case 3: Formulations Jose de Leon, MD

Valproate Case 3: Formulations Jose de Leon, MD Valproate Case 3: Formulations 2-12-16 Jose de Leon, MD 3.Valproate Case 3 Described in J Clin Psychiatry 2004;65:724-5 http://www.ncbi.nlm.nih.gov/pubmed/15163266 Pharmacological explanation provided

More information

Epilepsy T.I.A. Cataplexy. Nonepileptic seizure. syncope. Dystonia. Epilepsy & other attack disorders Overview

Epilepsy T.I.A. Cataplexy. Nonepileptic seizure. syncope. Dystonia. Epilepsy & other attack disorders Overview : Clinical presentation and management Markus Reuber Professor of Clinical Neurology Academic Neurology Unit University of Sheffield, Royal Hallamshire Hospital. Is it epilepsy? Overview Common attack

More information

Anticonvulsant Prior Authorization Request

Anticonvulsant Prior Authorization Request Anticonvulsant Prior Authorization Request Commonwealth of Massachusetts MassHealth Drug Utilization Review Program P.O. Box 2586, Worcester, MA 01613-2586 Fax: 1-877-208-7428 Phone: 1-800-745-7318 MassHealth

More information

ANTIEPILEPTIC Medicines

ANTIEPILEPTIC Medicines ANTIEPILEPTIC Medicines Treatment with antiepileptic medicines currently enables over 70% of people with epilepsy to live free of seizures. In the last few days years several new medicines have become

More information

Therapeutic drug monitoring of Antiepileptic drugs in serum: a fully automated approach

Therapeutic drug monitoring of Antiepileptic drugs in serum: a fully automated approach PO-CON1775E Therapeutic drug monitoring of Antiepileptic drugs in serum: ASMS 2017 TP450 Davide Vecchietti 1, Claudio Ghilardi 1, Katharina Kern 2, Stephane Moreau 3, Isabel Cabruja 1 1 Shimadzu Italia,

More information

Objectives. Amanda Diamond, MD

Objectives. Amanda Diamond, MD Amanda Diamond, MD Objectives Recognize symptoms suggestive of seizure and what those clinical symptoms represent Understand classification of epilepsy and why this is important Identify the appropriate

More information

Introduction to Pharmacology: Pearls and Tidbits for the Dravet Community

Introduction to Pharmacology: Pearls and Tidbits for the Dravet Community Introduction to Pharmacology: Pearls and Tidbits for the Dravet Community 2016 Dravet Syndrome Foundation Biennial Family& Professional Conference June 25, 2016 Coral Gables, FL Michelle Welborn, PharmD

More information

Modified release drug delivery system for antiepileptic drug (Formulation development and evaluation).

Modified release drug delivery system for antiepileptic drug (Formulation development and evaluation). TITLE OF THE THESIS / RESEARCH: Modified release drug delivery system for antiepileptic drug (Formulation development and evaluation). INTRODUCTION: Epilepsy is a common chronic neurological disorder characterized

More information

Quetiapine Case 2 Therapeutic Drug Monitoring Jose de Leon, MD

Quetiapine Case 2 Therapeutic Drug Monitoring Jose de Leon, MD Quetiapine Case 2 Therapeutic Drug Monitoring 1-27-16 Jose de Leon, MD 2. Quetiapine Case Therapeutic Drug Monitoring (unpublished) Educational Objectives At the conclusion of this presentation, the participant

More information

Clinical Policy: Clobazam (Onfi) Reference Number: CP.PMN.54 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

Clinical Policy: Clobazam (Onfi) Reference Number: CP.PMN.54 Effective Date: Last Review Date: Line of Business: HIM, Medicaid Clinical Policy: (Onfi) Reference Number: CP.PMN.54 Effective Date: 11.01.12 Last Review Date: 08.18 Line of Business: HIM, Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Newer AEDs compared to LVT as adjunctive treatments for uncontrolled focal epilepsy. Dr. Yotin Chinvarun. M.D. Ph.D.

Newer AEDs compared to LVT as adjunctive treatments for uncontrolled focal epilepsy. Dr. Yotin Chinvarun. M.D. Ph.D. Newer AEDs compared to LVT as adjunctive treatments for uncontrolled focal epilepsy Dr. Yotin Chinvarun. M.D. Ph.D. Chronology of antiepileptic drug introduction over the past 150 years 20 15 10 Perampanel

More information

7/31/09. New AEDs. AEDs. Dr. Yotin Chinvarun M.D. Ph.D. Comprehensive Epilepsy and Sleep disorder Program PMK hospital. 1 st genera*on AEDs

7/31/09. New AEDs. AEDs. Dr. Yotin Chinvarun M.D. Ph.D. Comprehensive Epilepsy and Sleep disorder Program PMK hospital. 1 st genera*on AEDs Dr. Yotin Chinvarun M.D. Ph.D. Comprehensive Epilepsy and Sleep disorder Program PMK hospital New AEDs AEDs NEW OLD Pregabalin Pregabalin 1 st genera*on AEDs Phenytoin Carbamazepine Valproate Phenobarbital

More information

Antiepileptics. Medications Comment Quantity Limit Carbamazepine. May be subject Preferred to quantity limit Epitol

Antiepileptics. Medications Comment Quantity Limit Carbamazepine. May be subject Preferred to quantity limit Epitol Market DC Antiepileptics Override(s) Approval Duration Prior Authorization 1 year Step Therapy Quantity Limit *Indiana Medicaid See State Specific Mandate below *Maryland Medicaid See State Specific Mandate

More information

New Patient Questionnaire - Epilepsy

New Patient Questionnaire - Epilepsy New Patient Questionnaire - Epilepsy Person completing this form: (if other than the patient) GENERAL SEIZURE HISTORY Relationship: When do you think your child had their first seizure? When was the last

More information

TRANSPARENCY COMMITTEE OPINION. 19 July 2006

TRANSPARENCY COMMITTEE OPINION. 19 July 2006 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 19 July 2006 Keppra 250 mg, film-coated tablets Box of 60 tablets (CIP code: 356 013-6) Keppra 500 mg, film-coated

More information

Chapter 31-Epilepsy 1. public accountant, and has begun treatment with lamotrigine. In which of the following activities

Chapter 31-Epilepsy 1. public accountant, and has begun treatment with lamotrigine. In which of the following activities Chapter 31-Epilepsy 1 Chapter 31. Epilepsy, Self-Assessment Questions 1. BW is a 28-year-old man recently diagnosed with partial seizures. He works as a certified public accountant, and has begun treatment

More information

CLINICIAN INTERVIEW AS i M: When you examine a clinical trial in new- onset epilepsy, how relevant are the results to your daily clinical practice?

CLINICIAN INTERVIEW AS i M: When you examine a clinical trial in new- onset epilepsy, how relevant are the results to your daily clinical practice? FROM CLINICAL TRIALS TO CLINICAL PRACTICE: TRANSLATING EPILEPSY RESEARCH INTO PATIENT CARE Interview with Jacqueline A. French, MD Dr Jacqueline A. French is a Professor in the Department of Neurology

More information

APPENDIX K Pharmacological Management

APPENDIX K Pharmacological Management 1 2 3 4 APPENDIX K Pharmacological Management Table 1 AED options by seizure type Table 1 AED options by seizure type Seizure type First-line AEDs Adjunctive AEDs Generalised tonic clonic Lamotrigine Oxcarbazepine

More information

Hormones & Epilepsy 18/07/61. Hormones & Women With Epilepsy (WWE) How different are women? Estradiol = Proconvulsant. Progesterone = Anticonvulsant

Hormones & Epilepsy 18/07/61. Hormones & Women With Epilepsy (WWE) How different are women? Estradiol = Proconvulsant. Progesterone = Anticonvulsant How different are women? AED choice in special population Women With Epilepsy (WWE) Updated 2018 Habitus Metabolism Co-morbidities Pasiri Sithinamsuwan Psychosocial stigma Phramongkutklao Hospital Hormonal

More information

EPILEPSY: SPECTRUM OF CHANGE WITH AGE. Gail D. Anderson, Ph.D.

EPILEPSY: SPECTRUM OF CHANGE WITH AGE. Gail D. Anderson, Ph.D. EPILEPSY: SPECTRUM OF CHANGE WITH AGE Gail D. Anderson, Ph.D. Incidence: 0.5% - 1.0% of U.S. population Peak incidence of onset: first 2 years of life, ages 5-7 years, early puberty and elderly. 125,000

More information

Epilepsies of Childhood: An Over-view of Treatment 2 nd October 2018

Epilepsies of Childhood: An Over-view of Treatment 2 nd October 2018 Epilepsies of Childhood: An Over-view of Treatment 2 nd October 2018 Dr Sophia Varadkar MRCPI, PhD Consultant Paediatric Neurologist and Honorary Senior Lecturer Great Ormond Street Hospital for Children

More information

Clinical Policy: Clobazam (Onfi) Reference Number: CP.PMN.54 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

Clinical Policy: Clobazam (Onfi) Reference Number: CP.PMN.54 Effective Date: Last Review Date: Line of Business: HIM, Medicaid Clinical Policy: (Onfi) Reference Number: CP.PMN.54 Effective Date: 11.01.12 Last Review Date: 11.18 Line of Business: HIM, Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Introduction. 1 person in 20 will have an epileptic seizure at some time in their life

Introduction. 1 person in 20 will have an epileptic seizure at some time in their life Introduction 1 person in 20 will have an epileptic seizure at some time in their life Epilepsy is diagnosed on the basis of two or more epileptic seizures. Around 450,000 people in the UK have epilepsy

More information

Epilepsy 7/28/09! Definitions. Classification of epilepsy. Epidemiology of Seizures and Epilepsy. International classification of epilepsies

Epilepsy 7/28/09! Definitions. Classification of epilepsy. Epidemiology of Seizures and Epilepsy. International classification of epilepsies Definitions Epilepsy Dr.Yotin Chinvarun M.D., Ph.D. Seizure: the clinical manifestation of an abnormal and excessive excitation of a population of cortical neurons Epilepsy: a tendency toward recurrent

More information

Basic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics

Basic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics Basic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics Learning Outcomes Define biopharmaceutics Describe 4 processes of pharmacokinetics Describe factors that affect medication absorption Describe

More information

Epilepsy 2005 ILAE Report

Epilepsy 2005 ILAE Report 1 Seizure & Epilepsy Care Gregory Krauss, MD Johns Hopkins University October 31, 2016 1 Epilepsy 2005 ILAE Report Seizure = a symptom Defined as paroxysmal change in behavior due to abnormal electrical

More information

Children Are Not Just Small Adults Choosing AEDs in Children

Children Are Not Just Small Adults Choosing AEDs in Children Children Are Not Just Small Adults Choosing AEDs in Children Natrujee Wiwattanadittakun, MD Neurology division, Department of Pediatrics, Chiang Mai University Hospital, Chiang Mai University 20 th July,

More information

Generic Name (Brand Name) Available Strengths Formulary Limits. Primidone (Mysoline) 50mg, 250mg -- $

Generic Name (Brand Name) Available Strengths Formulary Limits. Primidone (Mysoline) 50mg, 250mg -- $ MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Epilepsy P&T DATE: 2/15/2017 THERAPEUTIC CLASS: Neurologic Disorders REVIEW HISTORY: 2/16 LOB AFFECTED: Medi-Cal (MONTH/YEAR)

More information

New drugs necessity for therapeutic drug monitoring

New drugs necessity for therapeutic drug monitoring New drugs necessity for therapeutic drug monitoring Stephan Krähenbühl Clinical Pharmacology & Toxicology University Hospital Basel kraehenbuehl@uhbs.ch Drugs suitable for TDM Narrow therapeutic range

More information

Update in Clinical Guidelines in Epilepsy

Update in Clinical Guidelines in Epilepsy Why We Need Clinical Guidelines? Clinician needs advice! Update in Clinical Guidelines in Epilepsy Charcrin Nabangchang, M.D. Phramongkutklao College of Medicine Tiamkao S, Neurology Asia2013 Why We Need

More information

REGULATORY ASSESSMENT OF CRITICAL DOSE DRUGS / NARROW THERAPEUTIC RANGE DRUGS IN HONG KONG

REGULATORY ASSESSMENT OF CRITICAL DOSE DRUGS / NARROW THERAPEUTIC RANGE DRUGS IN HONG KONG REGULATORY ASSESSMENT OF CRITICAL DOSE DRUGS / NARROW THERAPEUTIC RANGE DRUGS IN HONG KONG CLIVE CHAN DRUG OFFICE DEPARTMENT OF HEALTH MAIN DRUG LEGISLATION Pharmacy and Poisons Ordinance (Chapter 138,

More information

Adjusting phenytoin dosage in complex patients: how to win friends and influence patient outcomes

Adjusting phenytoin dosage in complex patients: how to win friends and influence patient outcomes Adjusting phenytoin dosage in complex patients: how to win friends and influence patient outcomes Brian Hardy, PharmD, FCSHP, FCCP Coordinator Education and Clinical Programs Department of Pharmacy Sunnybrook

More information

Pharmacy Medical Necessity Guidelines: Anticonvulsants/Mood Stabilizers

Pharmacy Medical Necessity Guidelines: Anticonvulsants/Mood Stabilizers Pharmacy Medical Necessity Guidelines: Anticonvulsants/Mood Stabilizers Effective: December 18, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review

More information

Opinion 24 July 2013

Opinion 24 July 2013 The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 24 July 2013 FYCOMPA 2 mg, film-coated tablet B/7 (CIP: 34009 267 760 0 8) B/28 (CIP: 34009 268 447 4 5) FYCOMPA 4

More information

Epilepsy the Essentials

Epilepsy the Essentials INSTITUTE OF NEUROLOGY DCEE / NSE Epilepsy the Essentials Fergus Rugg-Gunn Consultant Neurologist Dept of Clinical and Experimental Epilepsy Institute of Neurology, University College London Epilepsy Society

More information

Review of Anticonvulsant Medications: Traditional and Alternative Uses. Andrea Michel, PharmD, CACP

Review of Anticonvulsant Medications: Traditional and Alternative Uses. Andrea Michel, PharmD, CACP Review of Anticonvulsant Medications: Traditional and Alternative Uses Andrea Michel, PharmD, CACP Objectives Review epidemiology of epilepsy Classify types of seizures Discuss non-pharmacologic and pharmacologic

More information

FINAL REPORT TO THE FLORIDA AGENCY FOR HEALTH CARE ADMINISTRATION (AHCA) Project 19

FINAL REPORT TO THE FLORIDA AGENCY FOR HEALTH CARE ADMINISTRATION (AHCA) Project 19 1 FINAL REPORT TO THE FLORIDA AGENCY FOR HEALTH CARE ADMINISTRATION (AHCA) Project 19 Prescription Utilization Patterns and Hospitalizations in Epilepsy Patients on Anti Epileptic Drugs Abraham G. Hartzema,

More information

Self Report Seizure Survey Summary 2017

Self Report Seizure Survey Summary 2017 Self Report Seizure Survey Summary 2017 Tetrasomy 18p 61 responses 33 had at least one seizure = 54% 8 had a seizure in the last year Valproate (Depakote) 7 Valproate (Depakote, Epilium) 2 Lamotrigene

More information

AN UPDATE ON ANTIEPILEPTIC AGENTS: FOCUS ON AN UPDATE ON ANTIEPILEPTIC AGENTS: FOCUS ON SECOND GENERATION TREATMENT OPTIONS

AN UPDATE ON ANTIEPILEPTIC AGENTS: FOCUS ON AN UPDATE ON ANTIEPILEPTIC AGENTS: FOCUS ON SECOND GENERATION TREATMENT OPTIONS Volume 24, Issue 1 October 2008 AN UPDATE ON ANTIEPILEPTIC AGENTS: FOCUS ON SECOND GENERATION TREATMENT OPTIONS Jason Richey, Pharm.D. Candidate Epilepsy is a neurological disorder characterized by sudden

More information

SAFE USE OF PERAMPANEL IN A CARRIER OF VARIEGATE PORPHYRIA: A CASE REPORT

SAFE USE OF PERAMPANEL IN A CARRIER OF VARIEGATE PORPHYRIA: A CASE REPORT SAFE USE OF PERAMPANEL IN A CARRIER OF VARIEGATE PORPHYRIA: A CASE REPORT S Balestrini 1-2, Y Hart 3, S Thunell 4, SM Sisodiya 1 1 NIHR University College London Hospitals Biomedical Research Centre, Department

More information

Prayer of the Epileptologist

Prayer of the Epileptologist Prayer of the Epileptologist Lord, grant that my work increase knowledge and help other men. Failing that, Lord, grant that it will not lead to man's destruction. Failing that, Lord, grant that my article

More information

APPENDIX T - Unit costs of anti-epileptic drugs for 2012 guideline

APPENDIX T - Unit costs of anti-epileptic drugs for 2012 guideline Drug name APPENDIX T - Unit costs of anti-epileptic drugs for 2012 guideline Unit costs and weighted average unit costs for drug used in the treatment of focal and generalised epilepsies Prescription Cost

More information

TIAGABINE. THERAPEUTICS Brands Gabitril see index for additional brand names. Generic? Yes

TIAGABINE. THERAPEUTICS Brands Gabitril see index for additional brand names. Generic? Yes TIAGABINE THERAPEUTICS Brands Gabitril see index for additional brand names Generic? Yes Class Anticonvulsant; selective GABA reuptake inhibitor (SGRI) Commonly Prescribed for (bold for FDA approved) Partial

More information

Epilepsy 101. Russell P. Saneto, DO, PhD. Seattle Children s Hospital/University of Washington November 2011

Epilepsy 101. Russell P. Saneto, DO, PhD. Seattle Children s Hospital/University of Washington November 2011 Epilepsy 101 Russell P. Saneto, DO, PhD Seattle Children s Hospital/University of Washington November 2011 Specific Aims How do we define epilepsy? Do seizures equal epilepsy? What are seizures? Seizure

More information

Shared Care Guideline. The Management of Epilepsies in Children

Shared Care Guideline. The Management of Epilepsies in Children THE SOUTH YORKSHIRE & BASSETLAW Shared Care Guideline For The Management of Epilepsies in Children Shared care guideline developed by: Sheffield Children's NHS Foundation Trust; Dr P Baxter Consultant

More information

ANTIEPILEPTIC DRUGS. Hiwa K. Saaed, PhD. Department of Pharmacology & Toxicology College of Pharmacy University of Sulaimani

ANTIEPILEPTIC DRUGS. Hiwa K. Saaed, PhD. Department of Pharmacology & Toxicology College of Pharmacy University of Sulaimani ANTIEPILEPTIC DRUGS Hiwa K. Saaed, PhD Department of Pharmacology & Toxicology College of Pharmacy University of Sulaimani 2017-18 Antiepileptic drugs (AEDs) Definitions and Terminology Historical overview

More information

Management of Epilepsy in Pregnancy

Management of Epilepsy in Pregnancy Management of Epilepsy in Pregnancy September 7, 2018 Stephanie Paolini, MD Clinical Instructor/Women s Neurology Fellow UPMC Neurology We ve come a long way Sterilization of people with epilepsy was legal

More information

Convegno Regionale SIN SNO Lazio. Dai trial alla pratica clinica: novità in terapia dell epilessia

Convegno Regionale SIN SNO Lazio. Dai trial alla pratica clinica: novità in terapia dell epilessia Convegno Regionale SIN SNO Lazio Dai trial alla pratica clinica: novità in terapia dell epilessia Roma, 24 Novembre 2017 Response to optimally used AED therapy Initial monotherapy Seizure-free:50% Altern.

More information

Medication Therapy Management program

Medication Therapy Management program Medication Therapy Management program Your one-on-one review of your medicines Be safe Feel good Save money Safe and sound never felt so good Get the most from your medicine therapy with a personal medicine

More information

Types of epilepsy. 1)Generalized type: seizure activity involve the whole brain, it is divided into:

Types of epilepsy. 1)Generalized type: seizure activity involve the whole brain, it is divided into: Types of epilepsy We have different types of epilepsy, so it is not one type of seizures that the patient can suffer from; we can find some patients with generalized or partial seizure. So, there are two

More information

Difficult to treat childhood epilepsy: Lessons from clinical case scenario

Difficult to treat childhood epilepsy: Lessons from clinical case scenario Difficult to treat childhood epilepsy: Lessons from clinical case scenario Surachai Likasitwattanakul, M.D. Department of Pediatrics Faculty of Medicine, Siriraj Hospital Natural history of Epilepsy Untreated

More information

The primary goal of antiepileptic drug

The primary goal of antiepileptic drug THE ROLE OF THERAPEUTIC DRUG MONITORING IN PATIENT CARE * Page B. Pennell, MD ABSTRACT The dose-response relationship for antiepileptic drugs (AEDs) varies enormously between and within individual patients.

More information

Antiepileptic Drugs (Anticonvulsants )

Antiepileptic Drugs (Anticonvulsants ) Antiepileptic Drugs (Anticonvulsants ) NEPHAR 305 Pharmaceutical Chemistry I Assist.Prof.Dr. Banu Keşanlı 1 Anticonvulsants Anticonvulsants, sometimes also called antiepileptics, belong to a diverse group

More information

The importance of pharmacogenetics in the treatment of epilepsy

The importance of pharmacogenetics in the treatment of epilepsy The importance of pharmacogenetics in the treatment of epilepsy Öner Süzer and Esat Eşkazan İstanbul University, Cerrahpaşa Faculty of Medicine, Department of Pharmacology and Clinical Pharmacology Introduction

More information

Chapter 24 Antiseizures

Chapter 24 Antiseizures Chapter 24 1. Introduction Epilepsy is a heterogeneous symptom complex a chronic disorder characterized by recurrent seizures. Seizures are finite episodes of brain dysfunction resulting from abnormal

More information

Seizures (epilepsy) and brain tumours - treatment

Seizures (epilepsy) and brain tumours - treatment Seizures (epilepsy) and brain tumours - treatment Seizures are the most common first (onset) symptom that leads to a brain tumour diagnosis in adults. Many people with brain tumours develop seizures later

More information

Pregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition)

Pregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition) Pregnancy General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition) In all women of child bearing potential Always discuss the possibility of pregnancy; half of all pregnancies are unplanned

More information

NonConvulsive Seizure

NonConvulsive Seizure Sample Protocol #5: Management of status epilepticus and seizures in hospitalized patients nconvulsive Seizure Patient presents with alteration of consciousness unexplained by other etiologies AND suspicious

More information

ZONISAMIDE THERAPEUTICS. Brands * Zonegran. Generic? Not in US. If It Doesn t Work * Class Antiepileptic drug (AED), structurally a sulfonamide

ZONISAMIDE THERAPEUTICS. Brands * Zonegran. Generic? Not in US. If It Doesn t Work * Class Antiepileptic drug (AED), structurally a sulfonamide Z:/3-PAGINATION/SBT/2-PROOFS/NWMS/9780521136723C111//9780521136723C111.3D 376 [376 380] ZONISAMIDE Brands Zonegran Generic? Not in US THERAPEUTICS Class Antiepileptic drug (AED), structurally a sulfonamide

More information

Safe Use of Medicines

Safe Use of Medicines Safe Use of Medicines Take your medicines the right way each day! From the National Institute on Aging 1 Table of Contents Read this booklet for practical tips to make sure you are taking all your medicines

More information

ARTICLES Monotherapy in adults and elderly persons

ARTICLES Monotherapy in adults and elderly persons ARTICLES Monotherapy in adults and elderly persons Edward Faught, MD Address correspondence and reprint requests to Dr. Edward Faught, Department of Neurology, University of Alabama at Birmingham Epilepsy

More information

Selection of Anti-Epileptic Medication in Newly Diagnosed Epilepsy

Selection of Anti-Epileptic Medication in Newly Diagnosed Epilepsy Selection of Anti-Epileptic Medication in Newly Diagnosed Epilepsy S Venkataraman *, CS Narayanan ** * Senior Consultant Neurologist, Mata Chanan Devi Hospital, New Delhi; ** Classified Specialist (Medicine

More information

Epilepsy at the Edges. Robert F Leroy MD Texas Epilepsy Group Neurological Clinic of Texas, PA

Epilepsy at the Edges. Robert F Leroy MD Texas Epilepsy Group Neurological Clinic of Texas, PA Epilepsy at the Edges Robert F Leroy MD Texas Epilepsy Group Neurological Clinic of Texas, PA Epilepsy at the Edges What is the current thinking about the diagnosis and treatment of epilepsy? What will

More information

Done by: Rola Awad Presented to : Dr. Diana Malaeb Date: 28/2/2013

Done by: Rola Awad Presented to : Dr. Diana Malaeb Date: 28/2/2013 Done by: Rola Awad Presented to : Dr. Diana Malaeb Date: 28/2/2013 1 Abbreviations AED: antiepileptic drug EEG: electroencephalography SJS: Stevens Johnson syndrome VA: Valproic acid GABA : Gamma amino

More information

8/30/10. How to use Antiepileptic drugs properly. 3nd generation AEDs. Introduction. Introduction. Introduction. AEDs. Dr.Yotin Chinvarun M.D., Ph.D.

8/30/10. How to use Antiepileptic drugs properly. 3nd generation AEDs. Introduction. Introduction. Introduction. AEDs. Dr.Yotin Chinvarun M.D., Ph.D. Introduction How to use Antiepileptic drugs properly Modern treatment of seizures started in 1850 with the introduction of bromides, based on the theory that epilepsy was caused by an excessive sex drive

More information

MEDICATIONS IN DISEASE TREATMENT. Diet, Medications, and Dietary Supplements. Over-the-Counter Drugs. Prescription Medications.

MEDICATIONS IN DISEASE TREATMENT. Diet, Medications, and Dietary Supplements. Over-the-Counter Drugs. Prescription Medications. Diet, Medications, and Dietary Supplements Chapter 19 MEDICATIONS IN DISEASE TREATMENT Prescription Medications Usually given to treat serious conditions May cause side effects Physician evaluates the

More information